Neurocritical Care News

The FDA has declined to approve a new drug application for roluperidone to treat negative symptoms in individuals with schizophrenia.

A firm specializing in brain-computer interface has received a U.S. patent for its Medusa Electrode, which translates specific neuromodulation connections into universal electroencephalography plugs.

The first subject has been dosed in a phase 1 clinical trial of an oral proteolysis-targeting chimera protein degrader to treat neurodegenerative diseases, according to the manufacturer.

In a cohort of post-9/11 United States military veterans, moderate, severe and penetrating traumatic brain injuries were associated with the subsequent development of brain cancer, according to research from JAMA Network Open.

The European Commission has authorized Skyclarys to treat Friedreich’s ataxia in adults and adolescents aged 16 years and older.

Deficits in processing speed negatively affects memory in individuals with acquired brain injury, strongly suggesting lack of memory recall is associated with poor processing and information acquisition, data show.

Physicians treating older veterans with dementia “should consider underlying cirrhosis” and use Fibrosis-4 as a screening tool to uncover reversible factors, such as hepatic encephalopathy, that may be associated with cognitive decline.

The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.

A French biotechnology company has announced a global license agreement with a California-based biotech firm to utilize the former’s platform technology for delivery of RNA-targeted therapeutics.

An Ohio-based medical device company has secured $85 million in financing to advance a pain management system targeting the central nervous system to help those who have undergone surgery or sustained damage from other events or conditions.